タンパク質治療薬の市場規模、シェア、成長分析、タイプ別、用途別、エンドユーザー別、機能別、地域別 - 産業予測、2025-2032年

タンパク質治療薬市場規模は、2023年に2,425億8,000万米ドルと評価され、2024年の2,571億3,000万米ドルから2032年には4,098億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.0％で成長する見通しです。

世界人口の高齢化によって慢性疾患の有病率が上昇し、特に糖尿病、自己免疫疾患、がんなどの疾患に対処するための効率的なタンパク質治療薬に対する需要が高まっています。従来の低分子医薬品とは異なり、生物製剤、特にモノクローナル抗体は、その有効性、副作用の少なさ、標的特異性から人気を集めています。タンパク質工学とバイオテクノロジーの進歩は、融合タンパク質や二重特異性抗体などの次世代生物製剤の技術革新に焦点を当て、この市場をさらに強化しています。さらに、モノクローナル抗体を利用したオーダーメイドのがん治療は、正確な治療のためにますます不可欠になっています。さらに、タンパク質代替療法（PRTs）は、希少疾患の研究を奨励する世界のイニシアチブによって大きな注目を浴びており、オリジナルの生物製剤の特許切れによるバイオシミラーの出現とともに、治療の選択肢を広げています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

タンパク質治療薬市場規模：タイプ別

• 市場概要
• モノクローナル抗体
• インスリン
• 融合タンパク質
• ヒト成長ホルモン
• エリスロポエチン
• インターフェロン

タンパク質治療薬市場規模：用途別

• 市場概要
• がん
• 代謝障害
• 免疫疾患
• 血液疾患
• がん
• ホルモン障害
• 遺伝性疾患
• その他

タンパク質治療薬市場規模：エンドユーザー別

• 市場概要
• 製薬会社
• ヘルスケアサービスプロバイダー
• 調査機関
• 学術調査機関

タンパク質治療薬市場規模：機能別

• 市場概要
• ワクチン
• 酵素と調節
• タンパク質診断

タンパク質治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（United States）
• Roche（Switzerland）
• Merck & Co.（United States）
• Pfizer（United States）
• AbbVie（United States）
• Sanofi（France）
• AstraZeneca（United Kingdom）
• Novartis（Switzerland）
• Bristol-Myers Squibb（United States）
• Abbott Laboratories（United States）
• GlaxoSmithKline（United Kingdom）
• Novo Nordisk（Denmark）
• Eli Lilly and Company（United States）
• Amgen（United States）
• Gilead Sciences（United States）
• Biogen（United States）
• Bayer（Germany）
• Takeda Pharmaceutical Company（Japan）
• CSL Behring（Australia）
• Teva Pharmaceutical Industries（Israel）

結論と提言

Protein Therapeutics Market size was valued at USD 242.58 billion in 2023 and is poised to grow from USD 257.13 billion in 2024 to USD 409.83 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The rising prevalence of chronic diseases, driven by an ageing global population, is fueling demand for efficient protein therapeutics, particularly to address conditions like diabetes, autoimmune disorders, and cancer. Unlike traditional small-molecule drugs, biologics, especially monoclonal antibodies, are gaining popularity due to their efficacy, fewer side effects, and targeted specificity. Advancements in protein engineering and biotechnology are further enhancing this market, with a focus on innovating next-generation biologics such as fusion proteins and bispecific antibodies. Moreover, tailored cancer therapies utilizing monoclonal antibodies are increasingly vital for precise treatment. In addition, protein replacement therapies (PRTs) are receiving significant attention, spurred by global initiatives encouraging research into rare diseases, alongside the emergence of biosimilars as original biologics' patents expire, broadening therapeutic options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Protein Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Protein Therapeutics Market Segments Analysis

Global Protein Therapeutics Market is segmented by Type, Application, End User, Function and region. Based on Type, the market is segmented into Monoclonal Antibodies, Insulin, Fusion Protein, Human Growth Hormone, Erythropoietin and Interferon. Based on Application, the market is segmented into Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical companies, Healthcare Service Providers, Research Organizations and Academic Research Institutes. Based on Function, the market is segmented into Vaccines, Enzymatic and Regulatory and Protein Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Protein Therapeutics Market

The Protein Therapeutics market is significantly driven by the rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular conditions, which are becoming increasingly widespread globally. This surge in chronic illnesses is a primary catalyst for the growing demand for innovative protein-based treatments, such as biologics and monoclonal antibodies. These advanced therapeutic options offer targeted treatment capabilities, allowing for more effective management of complex medical conditions while minimizing side effects. As healthcare providers seek to address these pressing health issues, the reliance on protein therapeutics continues to expand, shaping the future of medical treatments and improving patient outcomes.

Restraints in the Protein Therapeutics Market

Despite the effectiveness of protein therapeutics, several factors hinder their widespread adoption. Chief among these is the high cost associated with these treatments, which renders them inaccessible to numerous patients. Additionally, inadequate insurance coverage complicates the financial landscape, as reimbursement levels vary significantly across different regions. This variability particularly affects patients in emerging markets, where affordability becomes a major barrier. Such economic challenges ultimately restrict market growth, limiting the potential of protein therapeutics to reach those who could benefit most from them, thereby impeding progress in this vital healthcare sector.

Market Trends of the Protein Therapeutics Market

The Protein Therapeutics market is experiencing a significant upward trend, fueled by the rising demand for personalized medicine that tailors treatments to individual genetic profiles. This shift enhances treatment efficacy while minimizing adverse effects, thereby attracting a larger patient base, particularly for oncology and autoimmune disorders. The increased focus on targeted biologics and advanced protein therapies not only caters to the specific needs of patients but also drives innovation in drug development. As healthcare providers embrace personalized approaches, investment in research and technology for protein-based therapeutics will likely intensify, positioning this market for substantial growth and advancement in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Protein Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Human Growth Hormone
• Erythropoietin
• Interferon

Global Protein Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cancer
• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

Global Protein Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical companies
• Healthcare Service Providers
• Research Organizations
• Academic Research Institutes

Global Protein Therapeutics Market Size by Function & CAGR (2025-2032)

• Market Overview
• Vaccines
• Enzymatic and Regulatory
• Protein Diagnostics

Global Protein Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, End User, Function)
  • US
  • Canada
• Europe (Type, Application, End User, Function)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End User, Function)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End User, Function)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End User, Function)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations